Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pimodivir plus standard of care in non-hospitalized patients with influenza A at risk of complications
2017-002217-59Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Influenza A infection comparing Pimodivir + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to resolution of influenza-related symptoms. Started Nov 2017; status: terminated.
02
Drugs
pimodivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2017-002217-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002217-59.